GUBRA APS DK 1

The out‑licensed obesity program ABBV‑295 has entered a phase‑2 dose‑finding study, triggering a $50 million milestone payment to Gubra. In spring 2025 Gubra had already received a $350 million upfront payment from AbbVie; a further up to $1.875 billion in milestones plus tiered royalties are possible. The study will treat 360 obese or overweight adults over 52 weeks, with the primary endpoint being percent weight change at week 32. The stock has recently posted gains and, according to the chart, generated a buy signal after breaking above 400 DKK. » More on deraktionaer.de

Gubra reports significant progress in biotech, CRO and ventures in H1 2026, with the CRO business returning to profit and growing sequentially by 11%. GUB‑UCN2 started Phase I/IIa, and AbbVie program ABBV‑295 achieved a median weight loss of about 10% after 12 weeks in Phase I. Management confirmed the biotech guidance for 2026 and expects a solid second half for the CRO; Ventures is reviewing initial transactions. The share fell moderately in premarket trading by about 1.27% to $390 as investors weigh pipeline progress against volatile partner payments (H1 milestones DKK 30m vs DKK 2.4bn a year earlier). » More on de.investing.com

Gubra reported mixed Q1 2026 results: total revenue around $76 million, strong biotech growth driven by milestone payments, while the CRO segment faces macroeconomic headwinds and the EBIT margin fell to 0%. Three obesity candidates are slated for phase‑2 studies in 2026, including ABBV‑295 (partnership with AbbVie), BI 3034701 (Boehringer Ingelheim) and the in‑house GUB‑UCN2 with a muscle‑preserving mechanism of action. Gubra lowered guidance for external CRO growth to 0–10% and CRO EBIT margin to 10–15% and also launched the venture unit Gubra Ventures to raise external capital. » More on de.investing.com